Genotropin

Cantor Fitzgerald cut its Versartis Inc (NASDAQ: VSAR) target from $34 to $14 — and was still able to rate it Overweight. The stock dropped from $21.60 to $3.20 in Friday pre-market trading after the firm released negative Phase 3 data on its Somavaratan trial for pediatric growth hormone...